Evidence map›Paper›PMID 27558397›Full record

ArticleBMC public health2016

Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.

Robert J Blount, Minh-Chi Tran, Charles K Everett, Adithya Cattamanchi, John Z Metcalfe, Denise Connor, Cecily R Miller, Jennifer Grinsdale, Julie Higashi, Payam Nahid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Universal screening for latent and active tuberculosis (TB) in asylum seeking children, Bochum and Hamburg, Germany, September 2015 to November 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2018
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Robert J BlountDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA. Robert.Blount@ucsf.edu.
Minh-Chi TranDepartment of Internal Medicine, University of California, Davis, Sacramento, CA, USA. minhchi.tran@gmail.com.
Charles K EverettDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
Adithya CattamanchiDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
John Z MetcalfeDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.
Denise ConnorDepartment of Medicine, University of California, San Francisco, CA, USA.
Cecily R MillerDepartment of Medicine, University of California, San Francisco, CA, USA.
Jennifer GrinsdaleSan Francisco Department of Public Health, Population Health Division, Office of Equity and Quality Improvement, San Francisco, CA, USA.
Julie HigashiSan Francisco Department of Public Health, Population Health Division, Disease Prevention and Control Branch, San Francisco, CA, USA.
Payam NahidDivision of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA.

Funding

TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)R01AI104589 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAHID, PAYAM, SIGAL, GEORGE B · 2013 to 2017
$6.2M
Immunodiagnosis of Active Tuberculosis in HIV-infected PatientsK23HL094141 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA · 2009 to 2013
$760k
Effects of Air Pollution on Childhood Tuberculosis in Viet NamK23ES025807 · NIEHS · UNIVERSITY OF IOWA · PI BLOUNT, ROBERT J · 2015 to 2019
$756k
Effects of Traffic Pollution on Lung Immunity and Pneumonia in Persons with HIVF32ES022582 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLOUNT, ROBERT J · 2013 to 2014
$134k
NHLBI NIH HHS K23 HL094141NIAID NIH HHS R01 AI104589NIEHS NIH HHS F32 ES022582NIEHS NIH HHS K23 ES025807
6 · The paper itself

Abstract

backgroundInterferon-gamma release assays may be used as an alternative to the tuberculin skin test for detection of M. tuberculosis infection. However, the risk of active tuberculosis disease following screening using interferon-gamma release assays in immigrants is not well defined. To address these uncertainties, we determined the incidence rates of active tuberculosis disease in a cohort of high-risk immigrants with Class B TB screened with interferon-gamma release assays (IGRAs) upon arrival in the United States.

methodsUsing a retrospective cohort design, we enrolled recent U.S. immigrants with Class B TB who were screened with an IGRA (QuantiFERON ® Gold or Gold In-Tube Assay) at the San Francisco Department of Public Health Tuberculosis Control Clinic from January 2005 through December 2010. We reviewed records from the Tuberculosis Control Patient Management Database and from the California Department of Public Health Tuberculosis Case Registry to determine incident cases of active tuberculosis disease through February 2015.

resultsOf 1233 eligible immigrants with IGRA screening at baseline, 81 (6.6 %) were diagnosed with active tuberculosis disease as a result of their initial evaluation. Of the remaining 1152 participants without active tuberculosis disease at baseline, 513 tested IGRA-positive and 639 tested IGRA-negative. Seven participants developed incident active tuberculosis disease over 7730 person-years of follow-up, for an incidence rate of 91 per 100,000 person-years (95 % CI 43-190). Five IGRA-positive and two IGRA-negative participants developed active tuberculosis disease (incidence rates 139 per 100,000 person-years (95 % CI 58-335) and 48 per 100,000 person-years (95 % CI 12-193), respectively) for an unadjusted incidence rate ratio of 2.9 (95 % CI 0.5-30, p = 0.21). IGRA test results had a negative predictive value of 99.7 % but a positive predictive value of only 0.97 %.

conclusionsAmong high-risk immigrants without active tuberculosis disease at the time of entry into the United States, risk of progression to active tuberculosis disease was higher in IGRA-positive participants compared with IGRA-negative participants. However, these findings did not reach statistical significance, and a positive IGRA at enrollment had a poor predictive value for progressing to active tuberculosis disease. Additional research is needed to identify biomarkers and develop clinical algorithms that can better predict progression to active tuberculosis disease among U.S. immigrants.

Indexed as

Interferon-gamma Release TestsBiomarkersCaliforniaDisease ProgressionEmigrants and ImmigrantsFemaleHumansLatent TuberculosisMaleMycobacterium tuberculosisRetrospective StudiesSan FranciscoTuberculin TestTuberculosisBiomarkersActive tuberculosis diseaseChest x-ray (CXR)Foreign-bornImmigrantIncidence rateInterferon-gamma release assay (IGRA)Latent tuberculosis infection (LTBI)Preventive chemotherapyTuberculosis (TB)

Identifiers

PMID27558397
PMCPMC4997768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.